Envue Medical Inc's Business Segments

ENvue Medical, Inc., formerly NanoVibronix, Inc., is a Delaware corporation engaged in the research, development, production, marketing, and sale of medical devices focused on enteral feeding. The company operates through two wholly-owned subsidiaries: NanoVibronix Ltd., which develops non-invasive medical devices for biofilm prevention and pain therapy designed for home use, and ENvue Medical Holdings LLC, which is in the initial growth stage of commercializing medical devices for enteral feeding. ENvue's principal product is the FDA 510(k)-cleared ENvue System, a navigation platform that assists clinicians in the real-time insertion of feeding tubes into the digestive system of hospitalized patients requiring nutrition. The system is designed to improve patient outcomes by enabling faster and safer feeding tube placement, reducing risks such as lung misplacement and associated complications. ENvue's business model includes sales of the navigation system alongside recurring sales of proprietary disposable feeding tubes and accessories such as syringes. The company focuses on the U.S. acute care hospital market and began marketing and sales in early 2020. Its strategy centers on enhancing the safety, efficiency, and reliability of enteral feeding tube placement through advanced navigation-enabled devices and related disposables.

The Company operates through two primary segments: NanoVibronix and ENvue. NanoVibronix generates revenue by selling products directly to patients and through distributor agreements. ENvue generates revenue from sales of its Systems and Nasoenteral tubes. Non-allocated administrative and other expenses are reported under Corporate. The Chief Executive Officer, serving as the Chief Operating Decision Maker (CODM), reviews financial information by segment to allocate resources and assess performance based on each segment's loss from operations.